Claims:

1. Compound of the formula (I) or (II)



(I)



(II)

where

(A) R^1 in formula (I) is substituted or unsubstituted oxazolyl, indolyl, pyrrolyl, pyrazolyl, triazinyl, 2-oxodihydrobenzo[d][1,3]oxazinyl, 4-oxodihydroimidazolyl, 5-oxo-4H-[1,2,4]triazinyl, 3-oxo-4H-benzo[1,4]thiazinyl, tetrahydroquinoxalinyl, 1,1,3-trioxodihydro-2H-1λ^6-benzo[1,4]thiazinyl, 1-oxo-pyridyl, dihydro-2H-benzo[1,4]oxazinyl, 2-oxotetrahydrobenzo[e][1,4]diazepinyl, 2-oxodihydrobenzo[e][1,4]diazepinyl, 1H-pyrrolizinyl, phthalazinyl, 1-oxo-3H-isobenzofuranyl, 4-oxo-3H-thieno[2,3-d]pyrimidinyl, 3-oxo-4H-benzo[1,4]oxazinyl, [1,5]naphthyridyl, dihydro-2H-benzo[1,4]thiazinyl, 1,1-dioxodihydro-2H-benzo[1,4]thiazinyl, 2-oxo-1H-pyrido[2,3-b][1,4]oxazinyl, dihydro-1H-pyrido[2,3-b][1,4]oxazinyl, 1H-pyrrolo[2,3-b]pyridyl, benzo[1,3]dioxolyl, benzooxazolyl, 2-oxobenzooxazolyl, 2-oxo-1,3-dihydroindolyl, 2,3-dihydroindolyl, indazolyl, benzofuranyl, dihydrobenzofuranyl, tetrahydropyranyl, 2-oxopiperidinyl or 2-oxoazepanyl; or

(B) R^1 in formula (I) is aryl or heterocyclyl which is substituted by at least one substituent selected from C_{1-6}-alkoxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, C_{3-8}-cycloalkyl-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl, C_{0-6}-alkylcarbonylamino, C_{0-6}-alkylcarbonylamino-C_{1-6}-alkyl, C_{0-6}-alkylcarbonylamino-C_{1-6}-alkoxy, (N-C_{1-6}-alkyl)-C_{0-6}-alkylcarbonylamino-C_{1-6}-alkyl, (N-C_{1-6}-alkyl)-C_{0-6}-alkylcarbonylamino-C_{1-6}-alkoxy, C_{3-8}-cycloalkylcarbonylamino-C_{1-6}-alkyl, C_{3-8}-cycloalkylcarbonylamino-C_{1-6}-alkoxy, C_{1-6}-alkoxy-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkoxy-C_{1-6}-alkoxy, C_{1-6}-alkoxycarbonylamino-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonylamino-C_{1-6}-alkoxy, C_{1-6}-alkylaminocarbonylamino-C_{1-6}-alkyl, C_{1-6}-alkylaminocarbonylamino-C_{1-6}-alkoxy, C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkyl, C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkoxy, C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkoxy-C_{1-6}-alkyl, di-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkyl, di-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkoxy, C_{1-6}-alkylcarbonyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyloxy-C_{1-6}-alkyl,C_{1-6}-alkylcarbonyloxy-C_{1-6}-alkoxy, cyano-C_{1-6}-alkyl, cyano-C_{1-6}-alkoxy, C_{1-6}-alkoxycarbonyl-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl-C_{1-6}-alkoxy, C_{1-6}-alkylsulphonylamino-C_{1-6}-alkyl, C_{1-6}-alkylsulphonylamino-C_{1-6}-alkoxy, (N-C_{1-6}-alkyl)-C_{1-6}-alkylsulphonylamino-C_{1-6}-alkyl, (N-C_{1-6}-alkyl)-C_{1-6}-alkylsulphonylamino-C_{1-6}-alkoxy, amino-C_{1-6}-alkyl, amino-C_{1-6}-alkoxy, C_{1-6}-alkylamino-C_{1-6}-alkyl, C_{1-6}-alkylamino-C_{1-6}-alkoxy, di-C_{1-6}-alkylamino-C_{1-6}-alkyl, di-C_{1-6}-alkylamino-C_{1-6}-alkoxy, C_{1-6}-alkylsulphonyl-C_{1-6}-alkyl, C_{1-6}-alkylsulphonyl-C_{1-6}-alkoxy, carboxy-C_{1-6}-alkyl, carboxy-C_{1-6}-alkoxy, carboxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkylcarbonyl,

acyl-C_{1-6}-alkoxy-C_{1-6}-alkyl, (N-C_{1-6}-alkyl)-C_{1-6}-alkoxycarbonylamino, (N-hydroxy)-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkyl, (N-hydroxy)-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkoxy, (N-hydroxy)aminocarbonyl-C_{1-6}-alkyl, (N-hydroxy)aminocarbonyl-C_{1-6}-alkoxy, C_{1-6}-alkoxyaminocarbonyl-C_{1-6}-alkyl, C_{1-6}-alkoxyaminocarbonyl-C_{1-6}-alkoxy, (N-C_{1-6}-alkoxy)-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkyl, (N-C_{1-6}-alkoxy)-C_{1-6}-alkylaminocarbonyl-C_{1-6}-alkoxy, (N-acyl)-C_{1-6}-alkoxy-C_{1-6}-alkylamino, C_{1-6}-alkoxy-C_{1-6}-alkylcarbamoyl, (N-C_{1-6}-alkyl)-C_{1-6}-alkoxy-C_{1-6}-alkylcarbamoyl, C_{1-6}-alkoxy-C_{1-6}-alkylcarbonyl, C_{1-6}-alkoxy-C_{1-6}-alkylcarbonylamino, (N-C_{1-6}-alkyl)-C_{1-6}-alkoxy-C_{1-6}-alkylcarbonylamino, carbamoyl-C_{1-6}-alkyl, carbamoyl-C_{1-6}-alkoxy, C_{1-6}-alkylcarbamoyl, di-C_{1-6}-alkylcarbamoyl, C_{1-6}-alkylsulphonyl, C_{1-6}-alkylamidinyl, acetamidinyl-C_{1-6}-alkyl, O-methyloximyl-C_{1-6}-alkyl and O,N-dimethylhydroxylamino-C_{1-6}-alkyl; or

(C) R^1 in formula (I) is aryl or heterocyclyl which is substituted by at least one substituent selected from [1,2,4]-triazol-1-ylalkyl, [1,2,4]-triazol-1-ylalkoxy, [1,2,4]-triazol-4-ylalkyl, [1,2,4]-triazol-4-ylalkoxy, [1,2,4]-oxadiazol-5-ylalkyl, [1,2,4]-oxadiazol-5-ylalkoxy, 3-methyl-[1,2,4]-oxadiazol-5-ylalkyl, 3-methyl-[1,2,4]-oxadiazol-5-ylalkoxy, 5-methyl-[1,2,4]-oxadiazol-3-ylalkyl, 5-methyl-[1,2,4]-oxadiazol-3-ylalkoxy, tetrazol-1-ylalkyl, tetrazol-1-ylalkoxy, tetrazol-2-ylalkyl, tetrazol-2-ylalkoxy, tetrazol-5-ylalkyl, tetrazol-5-ylalkoxy, 5-methyltetrazol-1-ylalkyl, 5-methyltetrazol-1-ylalkoxy, thiazol-4-ylalkyl, thiazol-4-ylalkoxy, oxazol-4-ylalkyl, oxazol-4-ylalkoxy, 2-oxopyrrolidinylalkyl, 2-oxopyrrolidinylalkoxy, imidazolylalkyl, imidazolylalkoxy, 2-methylimidazolylalkyl, 2-methylimidazolylalkoxy, dioxolanyl, dioxanyl, dithiolanyl, dithianyl, pyrrolidinyl, piperidinyl, piperazinyl, pyrrolyl, 4-methylpiperazinyl, morpholinyl, thiomorpholinyl, 2-hydroxymethylpyrrolidinyl, 3-hydroxypyrrolidinyl, 3,4-dihydroxypyrrolidinyl, 3-acetamidomethylpyrrolidinyl, 3-C_{1-6}-alkoxy-C_{1-6}-alkylpyrrolidinyl, 4-hydroxypiperidinyl, 4-oxopiperidinyl, 3,5-dimethylmorpholinyl, 4,4-dioxothiomorpholinyl, 4-oxothiomorpholinyl, 2,6-dimethylmorpholinyl, 2-oxoimidazolidinyl, 2-oxooxazolidinyl, 2-oxopyrrolidinyl, 2-oxo-[1,3]oxazinyl, 2-oxotetrahydropyrimidinyl, 2-oxooxazolidinyl-C_{1-6}-alkyl, 2-oxooxazolidinyl-C_{1-6}-alkoxy, 1-C_{1-6}-alkoxy-C_{1-6}-alkylimidazol-2-yl, 1-C_{1-6}-alkoxy-C_{1-6}-alkyltetrazol-5-yl, 5-C_{1-6}-alkoxy-C_{1-6}-alkyltetrazol-1-yl and 2-C_{1-6}-alkoxy-C_{1-6}-alkyl-4-oxoimidazol-1-yl; or

(D) R^1 in formula (I) is aryl or heterocyclyl if n is 0 and X is -O-CH-R^{11}-CO-NR^9-, or if n and m are each 0 and X is –O-CH-R^{11}- and R^2 is phenyl substituted by C_{1-6}-alkoxybenzyloxy-C_{1-6}-alkoxy; or

(E) R^1 in formula (I) is aryl or heterocyclyl if n is 1 and Z is –alk-NR^9-, where alk is C_{1-6}-alkylene; or

(F) R^1 in formula (I) is aryl or heterocyclyl when R^2 is tetrazolyl or imidazolyl which may be substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, cyano-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, C_{1-6}-alkanoyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl, or C_{1-6}-alkoxy groups, or a C_{1-6}-alkylenedioxy group, and/or may be substituted by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical; or

(G) R^1 in formula (II) is aryl or heterocyclyl;

R^2 is phenyl, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, furyl, tetrazolyl or imidazolyl which radicals may be substituted by 1-3 halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, cyano-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, C_{1-6}-alkanoyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl, or C_{1-6}-alkoxy groups, or a C_{1-6}-alkylenedioxy group, and/or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical;

L1, L2, L3, L4 and L5 are each independently a bond, C_{1-8}-alkylene, C_{2-8}-alkenylene or C_{2-8}-alkynylene, or are absent;

T1, T2, T3 and T4 are each independently
(a) a bond, or are absent, or are one of the groups
(b) –CH(OH)-
(c) –CH(OR^6)-
(d) –CH(NR^5R^6)-
(e) –CO-
(f) –CR^7R^8-
(g) –O- or -NR^6-
(h) –$S(O)_{0-2}$-
(I) –SO_2NR^6-
(j) –NR^6SO_2-
(k) –$CONR^6$-
(l) –NR^6CO-
(m) –O-CO-
(n) –CO-O-
(o) –O-CO-O-
(p) –O-CO-NR^6-
(q) –N(R^6)-CO-N(R^6)-
(r) –N(R^6)-CO-O-
(s) pyrrolidinylene, piperidinylene or piperazinylene
(t) –C(R^{11})(R^{12})-,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R^3 is hydrogen, hydroxyl, C_{1-6}-alkoxy or C_{2-6}-alkenyloxy;

R^4 is hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{1-6}-alkoxy, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, benzyl, oxo, or a
R^{4a}-Z1-X1- group where R^{4a} is
(a) H-
(b) C_{1-6}-alkyl-

(c) C_{2-6}-alkenyl-
(d) hydroxy-C_{1-6}-alkyl-
(e) polyhydroxy-C_{1-6}-alkyl-
(f) C_{1-6}-alkyl-O-C_{1-6}-alkyl-
(g) aryl-
(h) heterocyclyl-
(i) arylalkyl-
(j) heterocyclylalkyl-
(k) aryloxyalkyl-
(l) heterocyclyloxyalkyl-
(m) $(R^5,R^6)N$-$(CH_2)_{1-3}$-
(n) $(R^5,R^6)N$-
(o) C_{1-6}-alkyl-$S(O)_{0-2}$-
(p) aryl-$S(O)_{0-2}$-
(q) heterocyclyl-$S(O)_{0-2}$-
(r) HO-SO_3- or salts thereof
(s) H_2N-C(NH)-NH-
(t) NC-

and the bonds starting from (n)-(t) lead to a carbon atom of the adjacent group and this carbon atom is saturated if the bond starts from a heteroatom;

Z1
(a) is a bond, is absent, or is one of the groups
(b) C_{1-6}-alkylene-
(c) C_{2-6}-alkenylene-
(d) –O-, -$N(R^{11})$-, -$S(O)_{0-2}$-
(e) –CO-
(f) –O-CO-
(g) –O-CO-O-
(h) –O-CO-$N(R^{11})$-
(i) -$N(R^{11})$-CO-O-
(j) –CO-$N(R^{11})$-
(k) –$N(R^{11})$-CO-
(l) –$N(R^{11})$-CO-$N(R^{11})$-
(m) –$CH(OR^9)$-

and the bonds starting from (d) and (f)-(m) lead to a carbon atom of the adjacent group and this carbon atom is saturated if the bond starts from a heteroatom;

X1
(a) is a bond, is absent, or is one of the groups
(b) –O-

(c) -N(R^{11})-

(d) -S(O)$_{0-2}$-

(e) –(CH_2)$_{1-3}$–;

or R^3 and R^4 in formula (I) together are a bond;

R^5 and R^6 are each independently hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, aryl-C_{1-6}-alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or a –SO- or –SO_2- group, and the additional nitrogen atom may optionally be substituted by C_{1-6}-alkyl radicals;

R^7 and R^8, together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two –O- or –S- atoms or –SO- or –SO_2- groups;

R^9 is hydrogen, C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, acyl or arylalkyl;

R^{10} is carboxyalkyl, alkoxycarbonylalkyl, alkyl or hydrogen;

R^{11} is hydrogen or C_{1-6}-alkyl;

R^{12} is hydrogen or C_{1-6}-alkyl;

U is hydrogen, C_{1-6}-alkyl, C_{3-8}-cycloalkyl, cyano, optionally substituted C_{3-8}-cycloalkyl, aryl, or heterocyclyl;

Q is ethylene or is absent (formula I) or is ethylene or methylene (formula II);

X is a bond, oxygen or sulphur, or is a >CH-R^{11}, >CHOR^9, -O-CO-, >CO, >C=NOR^{10}, -O-CHR^{11}- or -O-CHR^{11}-CO-NR^9- group and the bond starting from an oxygen or sulphur atom leads to a saturated carbon atom of the Z group or to R^1;

W is oxygen or sulphur;

Z is C_{1-6}-alkylene, C_{2-6}-alkenylene, hydroxy-C_{1-6}-alkylidene, -O-, -S-, -O-alk-, -S-alk-, -alk-O-, –alk-S- or –alk-NR^9-, where alk is C_{1-6}-alkylene; and where

(a) if Z is -O- or –S-, X is >CH-R^{11} and either R^2 contains an L1-T1-L2-T2-L3-T3-L4-T4-L5-U substituent or R^4 is a substituent other than hydrogen as defined above;
(b) if Z is –O-alk- or –S-alk-, X is >CH-R^{11}; and
(c) if X is a bond, Z is C_{2-6}-alkenylene, -alk-O- or –alk-S-,

n is 0 or 1;

m is 0 or 1;

and pharmaceutically usable salts thereof.

2. Compound according to Claim 1 of the formula (IA) or (IIA)



IA



IIA

where R^1, R^2, R^3, R^4, Q, W, X, Z, n and m are each as defined for the compounds of the formulae (I) or (II) according to Claim 1.

3. Compound according to Claim 1 or 2 where

R^1 is as defined for (A), (B), (C), (D), (E), (F) or (G), more preferably as specified for (A), (B), (C) or (D); R^2 is phenyl, cyclohexyl, tetrazolyl, unsubstituted or substituted by halogen, hydroxyl, cyano, trifluoromethyl, C_{1-6}-alkyl, halo-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl, cyano-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, C_{1-6}-alkanoyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyloxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonyl, C_{1-6}-alkoxy, C_{1-6}-alkylenedioxy, or by an L1-T1-L2-T2-L3-T3-L4-T4-L5-U radical; or naphthyl or acenaphthyl;

L1, L2, L3, L4 and L5 are each independently a bond, C_{1-8}-alkylene, C_{2-8}-alkenylene or C_{2-8}-alkynylene, or are absent;

T1, T2, T3 and T4 are each independently

(a) a bond, or are absent, or are one of the groups

(b) –CH(OH)-

(c) –CH(OR^6)-

(d) –CH(NR^5R^6)-

(e) –CO-

(f) –CR^7R^8-

(g) –O- or -NR^6-

(h) –$S(O)_{0-2}$-

(i) –SO_2NR^6-

(j) –NR^6SO_2-

(k) –$CONR^6$-

(l) –NR^6CO-

(m) –O-CO-

(n) –CO-O-

(o) –O-CO-O-

(p) –O-CO-NR^6-

(q) –N(R^6)-CO-N(R^6)-

(r) –N(R^6)-CO-O-

(s) pyrrolidinylene, piperidinylene or piperazinylene

(t) –C(R^{11})(R^{12})-,

where the bonds starting from (b)-(t) lead to a saturated or aromatic carbon atom of the adjacent group if the bond starts from a heteroatom, and where not more than two (b)-(f) groups, three (g)-(h) groups and one (i)-(t) group are present;

R^3 is hydrogen, hydroxyl, C_{1-6}-alkoxy or C_{2-6}-alkenyloxy;

R^4 is hydrogen, C_{1-6}-alkyl, C_{2-6}-alkenyl, C_{1-6}-alkoxy, hydroxy-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkyl or benzyl;

R^5 and R^6 are each independently hydrogen, C_{1-6}-alkyl or acyl, or, together with the nitrogen atom to which they are bonded, are a 5- or 6-membered heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom;

R^7 and R^8, together with the carbon atom to which they are bonded, are a 3-7-membered ring which may contain one or two –O- or –S- atoms;

R^9 is hydrogen, C_{1-6}-alkyl, acyl or arylalkyl;

U is hydrogen, C_{1-6}-alkyl, C_{3-8}-cycloalkyl, cyano, aryl or heterocyclyl;

Q is ethylene or is absent (formula (I)) and is ethylene or methylene (formula (II));

X is oxygen, sulphur or a $>CH_2$, $>CHOR^9$, -O-CO-, >CO or $–O-CH-R^{11}-CO-NR^9$- group;

W is oxygen or sulphur if R^3 is hydrogen;

Z is C_{1-6}-alkylene or -alk-O-;

n is 0 or 1;

m is 0 or 1;

and pharmaceutically useable salts thereof.

4. Compound according to Claim 1, wherein R^1 is 3-C_{1-6}-alkylindolyl, benzofuranyl, 4H-benzo[1,4]oxazin-3-onyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[1,4]thiazinyl, 3,3-di-C_{1-6}-alkyl-1,3-dihydroindol-2-onyl, 3,3-di-C_{1-6}-alkyl-1,3-dihydroindolyl, indolyl, 3-methylindolyl and spiro[cyclopropane-1,3']-2,3-dihydro-1H-indolyl, each of which may in particular be substituted by at least one substituent selected from C_{1-6}-alkoxy-C_{1-6}-alkoxy, C_{1-6}-alkoxy-C_{1-6}-alkyl, N-acetyl-C_{1-6}-alkoxy-C_{1-6}-alkylamino, C_{1-6}-alkanoylamido-C_{1-6}-alkyl, N-C_{1-6}-alkyl-C_{1-6}-alkanoylamido-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, triazol-1-yl-C_{1-6}-alkyl, tetrazol-1-yl-C_{1-6}-alkyl, tetrazol-2-yl-C_{1-6}-alkyl, tetrazol-5-yl-C_{1-6}-alkyl, C_{1-6}-alkoxycarboxyl-C_{1-6}-alkyl, pyrrolidinonyl-C_{1-6}-alkyl, imidazolyl-C_{1-6}-alkyl, cyano-C_{1-6}-alkyl, carboxy-C_{1-6}-alkyl, carboxy-C_{1-6}-alkoxy, C_{1-6}-alkoxycarbonyl-C_{0-6}-alkyl, C_{1-6}-alkylsulphonamidyl-C_{1-6}-alkyl, C_{1-6}-alkoxy-C_{1-6}-alkanoylamido, C_{1-6}-alkoxy-C_{1-6}-alkanoylamido-C_{1-6}-alkyl, N-(C_{1-6}-alkyl)-C_{1-6}-alkoxy-C_{1-6}-alkanoylamido, N-C_{1-6}-alkylcarbamoyl-C_{1-6}-alkyl, C_{3-8}-cycloalkanoylamido-C_{1-6}-alkyl, C_{1-6}-alkylaminocarbonylamino-C_{1-6}-alkyl, C_{1-6}-alkanoylamidomethylpyrrolidinyl, N-(C_{1-6}-alkoxy-C_{1-6}-alkyl)carbamoyl, N-(C_{1-6}-alkoxy-C_{1-6}-alkyl)-N-(C_{1-6}-alkyl)carbamoyl, N-(C_{1-6}-alkoxy-C_{1-6}-alkyl)imidazol-2-yl, hydroxy-C_{1-6}-alkyl, hydroxy-C_{1-6}-alkoxy, hydroxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, C_{1-6}-alkoxycarbonylamido-C_{1-6}-alkyl, amino-C_{1-6}-alkyl and C_{1-6}-alkylamino-C_{1-6}-alkyl.

5. Compound according to Claim 1, wherein R^2 is phenyl or halophenyl each substituted by C_{1-6}-alkoxybenzyloxy-C_{1-6}-alkoxy, C_{1-6}-alkoxyphenyl-C_{1-6}-alkoxy-C_{1-6}-alkoxy, C_{1-6}-alkylphenoxy-C_{1-6}-alkoxy, halobenzyloxy-C_{1-6}-alkoxy, halophenoxy-C_{1-6}-alkoxy, halophenoxy-C_{1-6}-alkoxy-C_{1-6}-alkyl, N-(halophenyl)pyrrolidin-3-yloxy or indol-4-yloxy-C_{1-6}-alkyl.

6. Compound according to Claim 1, wherein X is hydrogen, -O-CH_2-CO-NH-, -O-CH_2-CO-N(CH_3)- or -O-CH(CH_3)-CO-NH-.

7. Compound according to Claim 1, wherein Z is methylene, -$(CH_2)_2$-O- or -CH(CH_3)-.

8. Pharmaceutical preparations comprising a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2.

9. Use of a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2 in the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses.

10. Use of a compound of the formula (I), (IA), (II) or (IIA) according to Claims 1 and 2 for the preparation of a medicament, preferably a medicament for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenoses.